Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors in the central anxious system, conolidine modulates alternate molecular targets. A Science Developments analyze found that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://johnf420zce1.blogrenanda.com/profile